Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Blood Studies for Cardiovascular System I: Cardiac Biomarkers01:20

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

749
Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
749
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

516
Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
516

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Plasma proteomic profiles of Alzheimer's disease and neurodegeneration in African cohorts.

Nature communications·2026
Same author

[<sup>18</sup>F]RO948 Tau PET in early and late onset Alzheimer's disease: associations with plasma p-tau 217, atrophy and cognition.

European journal of nuclear medicine and molecular imaging·2026
Same author

Aβ- and tau-associated neuroinflammatory signatures in Alzheimer's disease.

Alzheimer's & dementia (New York, N. Y.)·2026
Same author

Association between automated brain volumetry and visual classification of hippocampal atrophy in MRI.

Neuroimage. Reports·2026
Same author

Tau extent outperforms tau load as a predictor of neurodegeneration in Alzheimer's disease.

Molecular neurodegeneration·2026
Same author

Comparison of [18F]flortaucipir and [18F]MK6240 for the detection of tau pathology in Alzheimer's disease (HEAD): a multicentre, prospective, cross-sectional, within-participant study.

Lancet (London, England)·2026
Same journal

Multimorbidity burden and patterns associated with DeepBrainNet-derived brain-age gap in dementia-free older adults: A community-based study.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Reply to "Shifting the emphasis of brain health literacy from individuals to systems to reduce inequalities".

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Shifting the emphasis of brain health literacy from individuals to systems to reduce inequalities.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Correlates and predictors of self-efficacy among dementia caregivers: D-CARE findings.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

What should convince a clinician of disease modification in Alzheimer's disease clinical trials?

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Primary cilia-extracellular vesicle crosstalk in Alzheimer's disease: Emerging mechanisms and biomarker potential.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
See all related articles

Related Experiment Video

Updated: Jan 7, 2026

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies
07:20

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies

Published on: January 28, 2014

37.1K

Biomarkers.

Luiza Santos Machado1, Guilherme Povala2, Ilaria Pola3

  • 1University of Gothenburg, Gothenburg, VG, Sweden.

Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association
|December 26, 2025
PubMed
Summary
This summary is machine-generated.

Researchers identified 485 glial-related cerebrospinal fluid (CSF) proteins altered in Alzheimer's disease (AD) and Parkinson's disease (PD), revealing potential biomarkers for neurodegenerative disease progression.

More Related Videos

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances
07:35

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances

Published on: October 11, 2018

7.9K
Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans
08:14

Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans

Published on: April 28, 2023

702

Related Experiment Videos

Last Updated: Jan 7, 2026

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies
07:20

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies

Published on: January 28, 2014

37.1K
Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances
07:35

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances

Published on: October 11, 2018

7.9K
Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans
08:14

Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans

Published on: April 28, 2023

702

Area of Science:

  • Neuroscience
  • Biomarker Discovery
  • Proteomics

Background:

  • Glial cells are crucial in Alzheimer's disease (AD) and Parkinson's disease (PD) pathophysiology.
  • Glial dysfunction contributes to neurodegeneration, but effective cerebrospinal fluid (CSF) biomarkers are limited.
  • Novel glial-derived CSF biomarkers are needed for understanding and monitoring AD and PD.

Purpose of the Study:

  • Identify novel glial-derived CSF biomarkers for AD and PD.
  • Investigate glial cell contributions to neurodegenerative disease progression.
  • Enhance understanding of glial heterogeneity in AD and PD.

Main Methods:

  • Selected astrocyte, oligodendrocyte, OPC, and microglia-enriched genes from transcriptomic data.
  • Cross-referenced gene lists with CSF proteomic data from AD and PD cohorts.
  • Utilized linear regression, clustering, and neuroimaging analyses to identify and validate biomarkers.

Main Results:

  • Identified 485 glial-related CSF proteins altered in AD or PD.
  • Found distinct glial protein clusters associated with AD pseudo-progression.
  • Demonstrated associations between glial protein clusters and amyloid-beta (Aβ) burden via PET imaging.

Conclusions:

  • Discovered 485 glial-related CSF proteins altered in AD and PD.
  • Uncovered glial protein clusters reflecting AD pseudo-progression and linked to Aβ burden.
  • Highlighted potential glial biomarkers for tracking neurodegenerative disease progression and heterogeneity.